Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17707875 | 0.90 | HTR1A (0.34) | NOTUMGABRA1GABRG2GABRB3FAAH | |
| SCHEMBL8593458 | 0.77 | L3MBTL1 (0.46) | NOTUMCYP1A2FGBL3MBTL1 | |
| SCHEMBL26141113 | 0.77 | NOTUM (0.66) | NOTUMLMNAGRM5TDP1 | |
| SCHEMBL19035394 | 0.76 | GABRA1 (0.35) | NOTUMGABRA1GABRG2GABRB3FAAH | |
| SCHEMBL23384700 | 0.76 | NOTUM (0.39) | NOTUMGRM5CYP11B1CYP11B2ADRB1 | |
| SCHEMBL22717412 | 0.76 | NOTUM (0.39) | NOTUMHTR2BGRM5CYP11B1CYP11B2 | |
| SCHEMBL27358451 | 0.76 | NPC1 (0.45) | NOTUMHPGDGRM5CYP11B1CYP11B2 | |
| SCHEMBL3595427 | 0.76 | HTR6 (0.51) | NOTUMCYP1A2GRM5CYP11B1CYP11B2 | |
| SCHEMBL27259961 | 0.76 | NOTUM (0.60) | NOTUMFGBL3MBTL1 | |
| SCHEMBL26700015 | 0.75 | TDP1 (0.41) | GABRA1GABRB2CYP11B1CYP11B2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2021026098-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| WO-2020150626-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-9920031-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9802915-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170260160-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| US-9688629-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-28 | — | — | US | disclosed |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-11 | — | — | US | disclosed |
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | NOTUM 3479/4885MAP3K5 292/4885GABRA1 1598/4885 |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | NOTUM 3479/4885MAP3K5 292/4885GABRA1 1598/4885 |
| US-20170260160-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | NOTUM 3479/4885MAP3K5 292/4885GABRA1 1598/4885 |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | NOTUM 3479/4885MAP3K5 292/4885GABRA1 1598/4885 |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | NOTUM 787/4885MAP3K5 1608/4885GABRA1 180/4885 |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | NOTUM 4166/4885MAP3K5 2412/4885GABRA1 1991/4885 |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | NOTUM 3840/4885MAP3K5 2358/4885GABRA1 1012/4885 |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | NOTUM 4166/4885MAP3K5 2412/4885GABRA1 1991/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | NOTUM 787/4885MAP3K5 1608/4885GABRA1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.